三诺生物：目前公司一代、二代CGM产品已在全球多个国家和地区完成注册

Core Viewpoint - Sanofi's i3CGM clinical data published in the international journal Diabetes Therapy indicates that the company's clinical trial design and data analysis have received recognition from top international experts, demonstrating global competitiveness in the CGM market [2] Group 1: Clinical Data and Recognition - Sanofi's CGM has met the FDA's performance indicators for iCGM, aligning with international standards [2] - Both domestic clinical data and international journal publications validate that Sanofi's CGM is competitive on a global scale [2] Group 2: Market Expansion and Commercialization - The company's first and second-generation CGM products have been registered in multiple countries and regions worldwide [2] - Sanofi is gradually commercializing its products in various countries' healthcare and cash markets [2] - The company plans to leverage the recent clinical data validation to further solidify its global market expansion [2]